{"id":59427,"date":"2026-06-04T22:36:50","date_gmt":"2026-06-04T13:36:50","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4572\/"},"modified":"2026-08-23T13:22:28","modified_gmt":"2026-08-23T04:22:28","slug":"company-4572","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4572\/","title":{"rendered":"CARNA BIOSCIENCES INC"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4572","DATE":"2026-01-09","longName":"Carna Biosciences, Inc.","company_name_ja":"","fullTimeEmployees":61,"address":"","phone":"","website":"https:\/\/www.carnabio.com","industry":"Biotechnology","sector":"Healthcare","regularMarketPrice":387,"financialCurrency":"","marketCap":7393,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":-113.62,"epsForward":0,"bookValue":0,"totalRevenue":579057000,"OperatingIncome":-2074972000,"operatingMargins":-358.33999999999997,"NetIncome":-2171470000,"profitMargins":-375,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":-702.25,"recommendationMean":0,"recommendationKey":"none","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T03:58:11.560180\", \"ticker\": \"4572\", \"ticker_full\": \"4572.T\", \"company_name\": \"CARNA BIOSCIENCES INC\", \"analyst_recommendations\": {\"has_data\": true, \"recommendation_key\": \"none\", \"recommendation_mean\": null, \"total_analysts\": null, \"strong_buy\": null, \"buy\": null, \"hold\": null, \"sell\": null, \"strong_sell\": null}, \"target_prices\": {\"has_data\": true, \"current\": 305.0, \"high\": null, \"low\": null, \"mean\": null, \"median\": null}, \"earnings_dates\": {\"has_data\": false}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 18.17, \"institution_pct\": 9.25, \"major_holders\": [{\"label\": \"\", \"value\": 18.17}, {\"label\": \"\", \"value\": 9.25}, {\"label\": \"\", \"value\": 11.3}, {\"label\": \"\", \"value\": 3.0}], \"institutional_holders\": [{\"holder\": \"SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF\", \"shares\": 4400, \"date_reported\": \"2022-09-30\", \"pct_held\": 0.03, \"pct_change\": 0.0, \"value\": 1342000}], \"mutualfund_holders\": []}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine\/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening\/profiling assay services comprising mobility shift assay\/IMAP and AFP-Glo assay; and cell-based assay services which include NanoBRET TE intracellular kinase assay and split luciferase protein-protein interaction detection assay. In addition, it engages in developing monzosertib, an orally bioavailable small molecule inhibitor of cell division cycle 7 (CDC7) kinase that is in Phase 1 to treat various cancer cell lines, including solid and blood cancers; docirbrutinib, an orally bioavailable, non-covalent pan-inhibitor of wild type and mutant Bruton's tyrosine kinases for the treatment of chronic lymphocytic leukemia and other B-cell malignancies; and sofnobrutinib, a non-covalent Bruton's tyrosine kinases which is in clinical development to treat inflammatory and immune disorders. Carna Biosciences, Inc. was incorporated in 2003 and is headquartered in Kobe, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T02:04:36.839952\", \"ticker\": \"4572\", \"ticker_full\": \"4572.T\", \"company_name\": \"CARNA BIOSCIENCES INC\", \"company_info\": {\"name_en\": \"CARNA BIOSCIENCES INC\", \"long_name\": \"Carna Biosciences, Inc.\", \"sector\": \"Healthcare\", \"industry\": \"Biotechnology\", \"website\": \"https:\/\/www.carnabio.com\", \"employees\": 61, \"country\": \"Japan\", \"city\": \"Kobe\", \"address\": \"BMA, 1-5-5 Minatojima-Minamimachi\", \"description\": \"Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine\/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening\/profiling assay services comprising mobility shift assay\/IMAP and AFP-Glo assay; and cell-based assay services which include NanoBRET TE intracellular kinase assay and split luciferase protein-protein interaction detection assay. In addition, it engages in developing monzosertib, an orally bioavailable small molecule inhibitor of cell division cycle 7 (CDC7) kinase that is in Phase 1 to treat various cancer cell lines, including solid and blood cancers; docirbrutinib, an orally bioavailable, non-covalent pan-inhibitor of wild type and mutant Bruton's tyrosine kinases for the treatment of chronic lymphocytic leukemia and other B-cell malignancies; and sofnobrutinib, a non-covalent Bruton's tyrosine kinases which is in clinical development to treat inflammatory and immune disorders. Carna Biosciences, Inc. was incorporated in 2003 and is headquartered in Kobe, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 387.6, \"deviation\": 3.97, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 327.68, \"deviation\": 22.99, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 365.63, \"deviation\": 10.22, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 347.19, \"deviation\": 16.08, \"trend\": \"up\"}}, \"financials\": {\"years\": [{\"year\": 2025, \"revenue\": 579057000.0, \"revenue_fmt\": \"\u00a56\u5104\", \"gross_profit\": 388148000.0, \"gross_profit_fmt\": \"\u00a54\u5104\", \"operating_income\": -2074972000.0, \"operating_income_fmt\": \"-\u00a521\u5104\", \"ebit\": -2159795000.0, \"ebit_fmt\": \"-\u00a522\u5104\", \"net_income\": -2171470000.0, \"net_income_fmt\": \"-\u00a522\u5104\", \"eps\": -113.62, \"operating_margin\": -358.34, \"total_assets\": 1229648000.0, \"total_assets_fmt\": \"\u00a512\u5104\", \"total_equity\": 309218000.0, \"total_equity_fmt\": \"\u00a53\u5104\", \"total_debt\": 714487000.0, \"total_debt_fmt\": \"\u00a57\u5104\", \"total_cash\": 516789000.0, \"total_cash_fmt\": \"\u00a55\u5104\", \"equity_ratio\": 25.15, \"de_ratio\": 2.31, \"current_ratio\": 6.99, \"operating_cf\": -2159363000.0, \"operating_cf_fmt\": \"-\u00a522\u5104\", \"investing_cf\": -25009000.0, \"investing_cf_fmt\": \"-\u00a525.0M\", \"financing_cf\": 604711000.0, \"financing_cf_fmt\": \"\u00a56\u5104\", \"free_cf\": -2168643000.0, \"free_cf_fmt\": \"-\u00a522\u5104\", \"net_margin\": -375.0, \"roe\": -702.25, \"roa\": -176.59}, {\"year\": 2024, \"revenue\": 636235000.0, \"revenue_fmt\": \"\u00a56\u5104\", \"gross_profit\": 465692000.0, \"gross_profit_fmt\": \"\u00a55\u5104\", \"operating_income\": -2076105000.0, \"operating_income_fmt\": \"-\u00a521\u5104\", \"ebit\": -2171018000.0, \"ebit_fmt\": \"-\u00a522\u5104\", \"net_income\": -2178576000.0, \"net_income_fmt\": \"-\u00a522\u5104\", \"eps\": -121.64, \"operating_margin\": -326.31, \"total_assets\": 2772115000.0, \"total_assets_fmt\": \"\u00a528\u5104\", \"total_equity\": 2475354000.0, \"total_equity_fmt\": \"\u00a525\u5104\", \"total_debt\": 61341000.0, \"total_debt_fmt\": \"\u00a561.3M\", \"total_cash\": 2108484000.0, \"total_cash_fmt\": \"\u00a521\u5104\", \"equity_ratio\": 89.29, \"de_ratio\": 0.02, \"current_ratio\": 12.28, \"operating_cf\": -1374806000.0, \"operating_cf_fmt\": \"-\u00a514\u5104\", \"investing_cf\": -13060000.0, \"investing_cf_fmt\": \"-\u00a513.1M\", \"financing_cf\": 567441000.0, \"financing_cf_fmt\": \"\u00a56\u5104\", \"free_cf\": -1387866000.0, \"free_cf_fmt\": \"-\u00a514\u5104\", \"net_margin\": -342.42, \"roe\": -88.01, \"roa\": -78.59}, {\"year\": 2023, \"revenue\": 1625889000.0, \"revenue_fmt\": \"\u00a516\u5104\", \"gross_profit\": 1450595000.0, \"gross_profit_fmt\": \"\u00a515\u5104\", \"operating_income\": -1116979000.0, \"operating_income_fmt\": \"-\u00a511\u5104\", \"ebit\": -1127395000.0, \"ebit_fmt\": \"-\u00a511\u5104\", \"net_income\": -1152895000.0, \"net_income_fmt\": \"-\u00a512\u5104\", \"eps\": -68.62, \"operating_margin\": -68.7, \"total_assets\": 4349891000.0, \"total_assets_fmt\": \"\u00a543\u5104\", \"total_equity\": 3877535000.0, \"total_equity_fmt\": \"\u00a539\u5104\", \"total_debt\": 182971000.0, \"total_debt_fmt\": \"\u00a52\u5104\", \"total_cash\": 2889101000.0, \"total_cash_fmt\": \"\u00a529\u5104\", \"equity_ratio\": 89.14, \"de_ratio\": 0.05, \"current_ratio\": 11.15, \"operating_cf\": -1677464000.0, \"operating_cf_fmt\": \"-\u00a517\u5104\", \"investing_cf\": -11376000.0, \"investing_cf_fmt\": \"-\u00a511.4M\", \"financing_cf\": 1182027000.0, \"financing_cf_fmt\": \"\u00a512\u5104\", \"free_cf\": -1688994000.0, \"free_cf_fmt\": \"-\u00a517\u5104\", \"net_margin\": -70.91, \"roe\": -29.73, \"roa\": -26.5}, {\"year\": 2022, \"revenue\": 1386748000.0, \"revenue_fmt\": \"\u00a514\u5104\", \"gross_profit\": 1215197000.0, \"gross_profit_fmt\": \"\u00a512\u5104\", \"operating_income\": -1269889000.0, \"operating_income_fmt\": \"-\u00a513\u5104\", \"ebit\": -1318089000.0, \"ebit_fmt\": \"-\u00a513\u5104\", \"net_income\": -1349539000.0, \"net_income_fmt\": \"-\u00a513\u5104\", \"eps\": -99.1, \"operating_margin\": -91.57, \"total_assets\": 4266453000.0, \"total_assets_fmt\": \"\u00a543\u5104\", \"total_equity\": 3641845000.0, \"total_equity_fmt\": \"\u00a536\u5104\", \"total_debt\": 300390000.0, \"total_debt_fmt\": \"\u00a53\u5104\", \"total_cash\": 3379048000.0, \"total_cash_fmt\": \"\u00a534\u5104\", \"equity_ratio\": 85.36, \"de_ratio\": 0.08, \"current_ratio\": 9.4, \"operating_cf\": -708390000.0, \"operating_cf_fmt\": \"-\u00a57\u5104\", \"investing_cf\": -125696000.0, \"investing_cf_fmt\": \"-\u00a51\u5104\", \"financing_cf\": 367006000.0, \"financing_cf_fmt\": \"\u00a54\u5104\", \"free_cf\": -834391000.0, \"free_cf_fmt\": \"-\u00a58\u5104\", \"net_margin\": -97.32, \"roe\": -37.06, \"roa\": -31.63}], \"has_data\": true}, \"dividends\": {\"history\": [], \"has_data\": false}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-59427","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CARNA BIOSCIENCES INC - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4572\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4572\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4572\/\",\"name\":\"CARNA BIOSCIENCES INC - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-04T13:36:50+00:00\",\"dateModified\":\"2026-08-23T04:22:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4572\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4572\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4572\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CARNA BIOSCIENCES INC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CARNA BIOSCIENCES INC - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4572\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4572\/","url":"https:\/\/japanir.jp\/en\/company\/company-4572\/","name":"CARNA BIOSCIENCES INC - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-04T13:36:50+00:00","dateModified":"2026-08-23T04:22:28+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4572\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4572\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4572\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"CARNA BIOSCIENCES INC"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/59427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=59427"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=59427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}